by Backoffice | Jun 17, 2022 | Studies and testing
Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production. The patient enrollment is now finalized in the randomized double-blind placebo-controlled phase II...
by Backoffice | Apr 29, 2022 | Trial results
The objective of the phase I clinical trial was to evaluate safety and provide proof of concept for efficacy of allogeneic adipose tissue-derived mesenchymal stromal cells (ASCs) injected into the major salivary glands in cancer patients with salivary glands damaged...
by Backoffice | Feb 27, 2022 | Collaborations
Cell2Cure has entered into a collaboration agreement with Endeavour Cells ApS, to collaborate on the preparation, conduct, management, and completion of an un-blinded phase I/II clinical trial in children with autism. The clinical trial title is “Effect of adipose...
by Backoffice | Feb 12, 2022 | Collaborations
Cell2Cure has entered into a sublicense agreement with Endeavour Cells ApS, which will allow Endeavour Cells ApS to develop, manufacture and commercialize ASCs for the treatment of Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD),...
by Backoffice | Jul 10, 2021 | Collaborations
Cell2Cure (C2C) has entered into a collaboration agreement with Cbio A/S to establish C2C´s own GMP facility for production of adipose tissue-derived mesenchymal stromal cell products (ASCs) in Cbio´s newly established and approved cell production facility,...
Recent Comments